Physician profile
Arthur David
NPI 1235135997
$4,019.94
in general payments reported to CMS, 2019-2025
25 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $226 · 2021: $281 · 2022: $488 · 2023: $813 · 2024: $712 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,369.23 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Orexo US, INC. | $462.31 | 2019-2025 | Zubsolv |
| Indivior INC. | $326.62 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $315.66 | 2020-2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $293.66 | 2019-2024 | Vivitrol, Vivitrol |
| Amarin Pharma, INC. | $212.14 | 2019-2021 | |
| Abbott Laboratories | $180.15 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Braeburn INC. | $173.91 | 2023-2025 | Brixadi |
| Exact Sciences Corporation | $153.56 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $77.38 | 2019-2025 | Trelegy Ellipta |
| Gilead Sciences, INC. | $73.48 | 2021-2022 | |
| Novo Nordisk INC | $64.97 | 2024-2025 | Ozempic, Wegovy |
| Pear Therapeutics (US), INC. | $57.13 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.66 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $30.76 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $28.15 | 2019-2021 | |
| Axsome Therapeutics, INC. | $24.60 | 2025 | Auvelity |
| Appliedvr INC | $21.67 | 2024 | Relievrx |
| Horizon Therapeutics Plc | $19.64 | 2023 | Krystexxa |
| Medtronic, INC. | $17.28 | 2025 | Inceptiv |
| Phadia US INC. | $16.71 | 2023 | Immunocap |
| Astrazeneca Pharmaceuticals Lp | $16.61 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.04 | 2022 | |
| Mdd US Operations, LLC | $12.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.